Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06029673 · ClinicalTrials.gov registry record · Phase 2
Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT06029673: Completed Phase 2 study, sponsored by Stanford University.
NCT06029673 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 69 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06029673, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
Breast pain following second-trimester abortion is common. Breast engorgement and milk leakage following second-trimester perinatal loss and abortion can cause both physical pain and emotional distress. Dopamine agonists have previously been shown to be effective in lactation inhibition for third-trimester fetal/neonatal loss or contraindications to breastfeeding. The investigator's prior work demonstrated that compared to placebo, a single dose of cabergoline was effective in preventing breast symptoms after abortion or loss 18-28 weeks. As lactogenesis starts as early as 16 weeks gestation, the investigators hope to determine the efficacy of cabergoline earlier in the second trimester,16-20 weeks.
Interventions
- DRUG Placebo
- DRUG Cabergoline 1 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06029673
The ClinicalTrials.gov registry entry for NCT06029673 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06029673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06029673 about?
NCT06029673 is a clinical study titled "Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss". Breast pain following second-trimester abortion is common. Breast engorgement and milk leakage following second-trimester perinatal loss and abortion can cause both physical pain and emotional distress. Dopamine agonists have previously been shown to be effective in lactation inhibition for third-tr...
What is the current status of trial NCT06029673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2024-02-07. Estimated completion is 2025-07-01.
What interventions are being tested in trial NCT06029673?
The interventions under investigation include: Placebo (DRUG), Cabergoline 1 MG (DRUG).
Who is sponsoring clinical trial NCT06029673?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.